Italy's Criminal Cases Could Drag On Longer: What Prescription Law Changes Mean for Defendants

The Italy Ministry of Justice is facing renewed pressure from Forza Italia, the center-right coalition partner, to fast-track a long-stalled reform that would reshape how criminal cases can expire under the statute of limitations. The push marks a critical juncture in Italy's ongoing debate over judicial efficiency versus defendants' rights—one that could determine whether cases drag on indefinitely or risk evaporating before a verdict is reached.

Why This Matters

• Legislative revival: A bill approved by the Italy Chamber of Deputies in January 2024 has sat dormant in the Senate for over two years; Forza Italia is now demanding it be put to a vote by summer.

• System overhaul: The proposal would scrap the "improcedibilità" mechanism introduced by the Cartabia reform, replacing it with a time-limited suspension of the statute of limitations after conviction.

• Coalition friction: While Forza Italia treats judicial reform as a flagship issue—especially after its referendum defeat—Fratelli d'Italia (Brothers of Italy) and the Lega are calibrating their support around broader government timelines, including PNRR (National Recovery and Resilience Plan) justice targets.

Forza Italia's Concrete Moves in Parliament

In recent days, Forza Italia has escalated from rhetoric to procedural action. Senator Pierantonio Zanettin, the party's lead voice on the Senate Justice Committee, formally requested that committee chair Giulia Bongiorno (Lega) schedule debate on the prescription reform bill. The text, which cleared the lower chamber more than 28 months ago, seeks to restore what the center-right calls "substantive prescription"—a system under which criminal liability expires after a set period, regardless of the trial stage.

Vice Justice Minister Francesco Paolo Sisto (Forza Italia) expressed cautious optimism: "An approval by summer? I hope so. Utinam! Would that heaven wills it." The religious Latin invocation underscores both the urgency and uncertainty surrounding the timeline.

Simultaneously, Forza Italia is advancing parallel justice initiatives. In the Chamber's Constitutional Affairs Committee, the party is pushing to enshrine the role of defense counsel in Italy's Constitution. And in a separate commission vote, newly appointed caucus leader Enrico Costa secured approval for a bill mandating that acquittal verdicts receive media coverage "commensurate with the space devoted to news of investigations"—a long-standing battle for Costa, who argues that reputational damage from publicized charges often outlives exoneration.

The party also briefed its deputies on the status of end-of-life legislation, signaling a broader re-engagement on civil rights dossiers after the coalition's setback in a recent national referendum.

What the Reform Actually Changes

Italy's prescription regime has ping-ponged through four major rewrites in less than a decade, each attempting to balance trial speed against the risk of "eternal proceedings."

The current Cartabia system (in force since October 2021) stops the statute of limitations after a first-instance verdict—whether conviction or acquittal—but introduces improcedibilità: appeals must conclude within 2 years, and final cassation within 1 year, or the case is automatically dismissed. This was designed to enforce the "reasonable duration" principle embedded in Article 6 of the European Convention on Human Rights.

Forza Italia's bill would:

Abolish improcedibilità entirely, allowing trials to continue past those deadlines.

Introduce limited suspension: The statute of limitations would pause for up to 24 months after a first-instance conviction, and for up to 12 months after an appellate conviction, but would resume if those time limits are exceeded, if the defendant is acquitted, or if the conviction is annulled.

In practical terms, the reform would restore the possibility that a case expires even after conviction—something the 2020 Bonafede law (which froze prescription indefinitely post-first-instance) sought to eliminate. The proposal leans closer to the 2017 Orlando reform, which suspended prescription for 18 months per appeal level but never imposed an outright freeze.

Coalition Dynamics and the Government's Calculus

While the entire center-right majority formally supports revisiting prescription, the pace and sequence of reforms remain contested.

Giulia Bongiorno, the Lega senator chairing the Justice Committee, acknowledged the request but said scheduling would be "balanced" with government timelines and PNRR benchmarks, which commit Italy to measurable improvements in judicial backlog clearance. Hearings will resume next week, she noted, but no floor vote has been calendared.

Ciro Maschio, head of the Chamber Justice Committee for Fratelli d'Italia, struck a similar cautious note: "There are regular majority meetings on justice. If there's a session, we'll discuss the agenda through the end of the legislature. The committee has a packed schedule; there will be plenty of work." His comments suggest Fratelli d'Italia is deferring to Prime Minister Giorgia Meloni, who has previously signaled that judicial separation of prosecutorial and judicial careers takes priority over prescription.

This internal tension reflects deeper ideological splits. Forza Italia frames prescription as a guarantist principle, protecting defendants from indefinite legal jeopardy. Fratelli d'Italia, by contrast, has historically emphasized law-and-order credentials and appears wary of legislation that could be spun as lenient on crime, even as the party filed its own bill in December 2025 to repeal the Bonafede freeze.

Opposition Critique and the Call for Structural Reform

Center-left lawmakers are attacking the revival on multiple fronts. Debora Serracchiani and Andrea Orlando, both from the Democratic Party, published a joint appeal in Il Sole 24 Ore urging the government to "resume a serious discussion on how justice functions and restore dialogue among all components of the judiciary, preventing the trenches dug in recent weeks from deepening and enduring."

Their critique rests on two pillars:

• Efficacy concerns: Opposition figures argue that tinkering with prescription timelines does nothing to address Italy's chronic trial delays. They advocate investing in court digitization, hiring more judges and support staff, and streamlining procedural rules—measures embedded in the PNRR but lagging in implementation.

• Risk of impunity: The Democratic Party attempted to carve out exemptions for serious crimes—workplace fatalities, human trafficking, environmental disasters, revenge porn, torture—from any expanded prescription windows, arguing that justice for victims should not be time-barred. Those amendments were defeated in committee.

Legal scholars and the Union of Italian Criminal Chambers have also questioned whether a new prescription regime could survive constitutional scrutiny, citing potential conflicts with the right to a fair trial, the presumption of innocence, and the rehabilitative purpose of punishment.

Impact on Residents and Legal Practitioners

For anyone navigating Italy's criminal justice system—whether as defendant, plaintiff, or witness—the stakes are tangible.

If the reform passes: Cases that might currently be dismissed for exceeding appeal deadlines could continue, potentially for years, if the statute of limitations has not yet expired. This cuts both ways: prosecutors gain more runway to secure convictions, but defendants face prolonged uncertainty and legal expense.

If the status quo holds: The Cartagia improcedibilità mechanism remains the backstop, incentivizing—at least in theory—judicial efficiency but also creating a scenario in which serious cases can evaporate on procedural grounds rather than substantive acquittal.

For defense attorneys, the debate is existential. Many in the bar view indefinite proceedings as a violation of due process; others worry that reintroducing broad prescription windows will allow well-resourced defendants to run out the clock through tactical appeals.

First President of the Cassation, Giovanni Mammone, has warned that eliminating prescription altogether could swell the appellate caseload by nearly 50%, adding roughly 20,000–25,000 cases annually that would otherwise have expired—a burden Italy's understaffed courts are ill-equipped to absorb.

What Happens Next

Bongiorno's commitment to resume hearings signals that the bill is no longer in deep freeze, but passage remains contingent on three variables:

Government prioritization: Will Meloni's cabinet treat prescription as urgent, or will it wait until the judicial-career separation bill clears both chambers?

PNRR compliance: Brussels is monitoring Italy's justice-reform milestones closely; any measure that risks inflating caseloads or delaying trials could jeopardize tranche disbursements.

Internal consensus: Forza Italia's vigor notwithstanding, a fractured majority could stall the bill indefinitely or water it down through amendments.

Vice Minister Sisto's invocation of divine intervention may be more than rhetorical flourish. Barring a sudden alignment of political will, the odds of a final vote before the summer recess—let alone before the legislature's end—remain uncertain. For Italy's overcrowded courts and the millions of citizens awaiting verdicts, the waiting game continues.